For Jerry, playing with his grandkids again & getting back on his boat has not only been lifechanging, but lifesaving. With the help of Rahul Banerjee, MD, FACP's research study, funded by Conquer Cancer, Jerry's back to doing what he enjoys. Jerry's story: conquer.org/impact/your-st…

Looking so forward to this week at #IMS2024 discussing and disseminating the latest #myeloma research!! Anyone registered to attend #IMS2024 in Rio can attend this Wednesday meeting!! THE BEST #multidisciplinary speakers and allied health abstracts!! Link to agenda below👇👇👇

Come support our team, plasma peeps! last week of fundraising for research. Help us reach our goal. We are close to 50 K already and hoping we can surpass that. support.myeloma.ca/site/TR/Multip… with Hamilton Health Sciences Myeloma Canada McMaster Research ECRI - ESCARPMENT CANCER RESEARCH INSTITUTE

chadi nabhan MD, MBA, FACP Vincent Rajkumar Westby Fisher, MD Shaalan Beg MD MBA FASCO Aaron Goodman - “Papa Heme” Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Nathan A. Pennell MD, PhD, FASCO I think your next book should be on why doctors don't need MOC and surveys and how it doesn't help patient care. In no way does it advance medicine nor outcomes of patients. The lay public, especially decision-makers, need to understand this #DoctorsVoice

#SOHO2024 Celebrating Krina Patel in her new role as Myeloma Section Chief at MD Anderson Cancer Center Congratulations 🎊 Sagar Lonial MD Nina Shah Thanos Dimopoulos

I'm incredibly honored & very grateful to my former boss & mentor Robert Z. Orlowski whose guidance and support have been instrumental in my journey. I owe much of this achievement to your leadership and belief in me. Excited for the path ahead as we continue advancing care for MM pts!

I’m thrilled to see the third drug targeting the HHLA2(B7H7, B7y)-KIR3DL3 pathway moving into clinical trials soon. This is a first-in-class T cell engager targeting both HHLA2 and CD3.

My Tue #HealthcareUnfiltered pod is W ⁦Yelak Biru⁩ CEO of ⁦International Myeloma Foundation⁩ who shares his inspiring journey when Dx W MM in his 20s & where he is now. What’s the future vision of the IMF? A must watch/listen. ⁦Vincent Rajkumar⁩ ⁦Joseph Mikhael⁩ ⁦Kathy Giusti⁩

We are excited to announce the publication of our article on the 5 Ts of treatment disparities in multiple myeloma in Latin America. We discuss the challenges in Tests, Therapies, Transplant, T Cell Redirecting Therapy (CAR T cells and bispecifics) , and Trials. By overcoming

I am speechless. Anthem Blue Cross and Blue Shield “peer” denied dara for my patient with NDMM citing no proof that it changes outcomes and did not know know diagnostic criteria for myeloma. Shame on you!

Adeel Khan MD MPH MS Why do I need to battle when there is a ph2 AND ph3 RCT proving the benefit? It’s malpractice at this point to treat with RVD.

Fantastic celebration of City of Hope OC

"While avoiding to die, don't forget to live!" From time to time, we need to rebalance between surviving and living life, but, this is a good north star to have! #mmsm

Was so grateful to attend African American Day Parade’s Second Annual Community Literacy, Health, and Culture Celebration last weekend with the Montefiore Sickle Cell Team and help spread knowledge about Sickle Cell Disease. #SickleCellAwarenessMonth #sicklecelldisease

This week's paper edition of The Lancet Haematology: a picture worth a thousand words that I hadn't seen before! Great graphic by Van de Donk Ajai Chari marivi mateos summarizing all possible methods of bsAb failure in #MMsm and potential strategies to overcome. thelancet.com/journals/lanha…

Marilyn and Stanley M. Katz Institute for Immunotherapy for Cancer and Inflammatory Disorders Montefiore Einstein Institute for Immunotherapy is established. 47 PIs of the institute are doing cutting-edge basic and clinical research and are developing novel immunotherapies.

Honored to be the founding Director of Marilyn and Stanley M. Katz Institute for Immunotherapy for Cancer and Inflammatory Disorders! 47 PIs who are doing cutting-edge basic and clinical research and are developing novel immunotherapies: montefioreeinstein.org/cancer/researc…

Two amazing leaders, two well-earned promotions! 👏 Congrats to Surbhi Sidana, MD (Stanford BMT & Cell Therapy) & Prasanna Jagannathan (Stanford Infectious Diseases Fellowship) on their advancement to Associate Professors!

My journey of 30 years in the clinical research field in a rare disease! BU Amyloidosis Center Defying the Odds: 30 Years in AL Amyloidosis Research, Recent Barriers to Clinical Trial Enrollment pubmed.ncbi.nlm.nih.gov/39293090/

Thank you Vania for opening Brazil for #IMS24 Myeloma Society meeting and being one of the hosts. 🙏🏼 #mmsm